Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sanofi

New Covid vaccine 100% effective against severe disease, data suggests

A Covid-19 vaccine that showed it is 100 per cent effective in preventing severe disease and hospitalisation in its trial data is seeking regulatory approval.

Evening Standard

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are

Sanofi and GSK seek approval for Covid-19 vaccine

Sanofi and GSK seek approval for Covid-19 vaccine

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

New Covid vaccine 100% effective against severe disease, manufacturers say

French pharmaceutical Sanofi and its British partner GlaxoSmithKline hope their vaccine will also be used as a booster

The Independent UK

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Hopeful Golden Cross Forms On Sanofi's Chart

If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ:SNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Regeneron Scores Quarterly Beat — But How Long Will Its Covid Tailwind Persist?

Regeneron snagged a quarterly beat Friday, reporting sales growth almost entirely attributed to its Covid cocktail — and REGN stock rose.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Sanofi: Q4 Earnings Insights

Sanofi: Q4 Earnings Insights

Sanofi (NASDAQ:SNY) reported its Q4 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours.

Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars

Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars

Sanofi SA's (NASDAQ: SNY)

A Preview Of Sanofi's Earnings

A Preview Of Sanofi's Earnings

Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will likely report an Earnings Per Share (EPS) of $0.72.

What Does Sanofi's Debt Look Like?

What Does Sanofi's Debt Look Like?

Over the past three months, shares of Sanofi (NASDAQ:SNY) increased by 1.88%. Before we understand the importance of debt, let us look at how much debt Sanofi has.

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

Organisations

Regeneron Pharmaceuticals Inc

GlaxoSmithKline

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

277,908 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play